Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis

被引:0
|
作者
Yujia Wang
Lushuang Xu
Yang Liu
Yuzhe Hu
Qiang Shi
Lixue Jin
Lijun Yang
Pingzhang Wang
Kunshan Zhang
Xiaojun Huang
Qing Ge
Jin Lu
机构
[1] Peking University,Department of Immunology, School of Basic Medical Sciences, NHC Key Laboratory of Medical Immunology
[2] Peking University People’s Hospital and Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation
[3] Peking University,School of Life Sciences, Center for Bioinformatics
[4] Tongji Hospital,Translational Stem Cell Research Center
[5] Tongji University School of Medicine,Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences
[6] Peking University,Collaborative Innovation Center of Haematology
[7] Soochow University,undefined
[8] Peking University Health Sciences Center,undefined
来源
关键词
Immunoglobulin light chain amyloidosis; Single-cell RNA sequencing; Plasma cells; Natural killer cells;
D O I
暂无
中图分类号
学科分类号
摘要
Immunoglobulin light chain amyloidosis (AL amyloidosis) is characterized by the presence of B cells producing amyloidogenic immunoglobulin light chains (LCs). The low frequency of aberrant B cells in AL is often masked by a polyclonal B cell background, making it difficult for treatment. We analyzed the single-cell RNA sequencing data from GEO database to compare the plasma cell (PCs) in four individuals with AL amyloidosis, one AL subject after treatment, and six healthy controls. High interindividual variability in AL-derived PCs in their expression pattern of known overexpressed genes in multiple myeloma and their usage of V regions in LCs was demonstrated. We also found overexpression of MHC class I molecules as one of the common features of clonal PCs in individuals with AL amyloidosis. Significantly reduced frequencies of circulating natural killer (NK) cells were also observed in a small cohort of AL patients when compared to healthy controls. These data demonstrate that aberrant PCs in AL has a highly diverse transcriptome, an upregulation of MHC, and a dampened capability of immunosurveillance by reduction of circulating NK frequencies. The analysis of clonal PCs at single cell level may provide a better approach for precise molecular profiling and diagnosis of AL amyloidosis.
引用
收藏
页码:231 / 242
页数:11
相关论文
共 50 条
  • [31] Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias
    Kourelis, Taxiarchis V.
    Kumar, Shaji K.
    Go, Ronald S.
    Kapoor, Prashant
    Kyle, Robert A.
    Buadi, Francis K.
    Gertz, Morie A.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Leung, Nelson
    Dingli, David
    Lust, John A.
    Lin, Yi
    Zeldenrust, Stephen R.
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (11) : 1051 - 1054
  • [32] Clonal heavy and light chain immunoglobulin DNA in plasma/serum of AIDS lymphoma patients
    Wagner-Johnston, Nina D.
    Nurmemet, Dilber
    Gocke, Christopher
    Lin, Lan
    Lemas, Victor M.
    Martinez-Maza, Otoniel
    Ambinder, Richard F.
    [J]. BLOOD, 2007, 110 (11) : 471A - 472A
  • [33] How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis)
    Chaulagain, Chakra P.
    Herlitz, Leal C.
    Fu, Julie
    Bilani, Nadeem
    Lucitt, Camerun
    Comenzo, Raymond L.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : E826 - E831
  • [34] Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
    Premkumar, Vikram
    Comenzo, Raymond
    Lentzsch, Suzanne
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : 686 - 688
  • [35] Therapy for immunoglobulin light chain amyloidosis: the new and the old
    Gertz, MA
    Lacy, MQ
    Dispenzieri, A
    [J]. BLOOD REVIEWS, 2004, 18 (01) : 17 - 37
  • [36] Hereditary systemic immunoglobulin light-chain amyloidosis
    Benson, Merrill D.
    Liepnieks, Juris J.
    Kluve-Beckerman, Barbara
    [J]. BLOOD, 2015, 125 (21) : 3281 - 3286
  • [37] Treatment Tolerability in Patients with Immunoglobulin Light Chain Amyloidosis
    Rizio, Avery A.
    White, Michelle K.
    McCausland, Kristen L.
    Quock, Tiffany P.
    Guthrie, Spencer D.
    Yokota, Miyo
    Bayliss, Martha S.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2018, 11 (08): : 430 - 437
  • [38] Chronic myopathy due to immunoglobulin light chain amyloidosis
    Manoli, Irini
    Kwan, Justin Y.
    Wang, Qian
    Rushing, Elisabeth J.
    Tsokos, Maria
    Arai, Andrew E.
    Burch, Warner M.
    Dispenzieri, Angela
    McPherron, Alexandra C.
    Gahl, William A.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2013, 108 (04) : 249 - 254
  • [39] Immunoglobulin light chain amyloidosis involved multiple organs
    Bai, J.
    Qiao, J.
    Fang, H.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2020, 113 (06) : 430 - 430
  • [40] Stem cell transplantation for immunoglobulin light chain amyloidosis
    Sher, Taimur
    Gertz, Morie A.
    [J]. CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 129 - 137